<DOC>
	<DOCNO>NCT01417455</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) ankylose spondylitis ( AS ) characterize chronic systemic inflammation share common pathogenic pathway . In disease , cytokine like TNF ( tumor necrosis factor ) interleukin ( IL ) -17 , know pro-inflammatory osteoclastogenic effect , relevant player , however , RA characterize bone erosion , AS favor bone overgrowth . Understanding paradox may hold key good management disease . Our hypothesis difference cellular environment intracellular signaling AS RA . To test hypothesis evaluate cytokine milieu , kinetics bone cell differentiation activity untreated immunosuppressed RA AS patient . We also perform observation patient expose targeted treatment .</brief_summary>
	<brief_title>Differences Bone Cell Activity Between Rheumatoid Arthritis Ankylosing Spondylitis</brief_title>
	<detailed_description>Objectives : 1 . Assess influence immune system cell modulation bone turnover patient RA , AS healthy donor ( Task 2 ) . 2 . Analyze osteoclast precursor differentiation fully functional osteoclast subgroup patient RA , AS healthy donor ( Task 3 , 4 6 ) . 3 . Study osteoblast differentiation potential activity subgroup patient RA AS ( Task 5 6 ) 4 . Assess effect therapy bone cell differentiation function subgroup patient RA AS treat TNF-blockers ( Task 2 , 3 , 4 5 ) . Work program timetable Starting date : July 2011 . Finishing date : July 2013 Task 1 - Patients Patients RA diagnosis ( accord revise American Rheumatism Association criterion , 1988 ) AS diagnosis ( accord European Spondyloarthropathy Study Group criterion , 1991 ) follow Rheumatology Bone Metabolic Diseases Department Hospital de Santa Maria ( HSM ) recruit study . Twenty-five patient active RA ( Disease Activity Score 28 ( DAS28 ) &gt; 3.2 ) 25 patient active AS ( Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; 4 ) include study . Fifteen healthy donor , sex age match , recruit use control group . Patients submit clinical protocol include information sex , age , disease duration , previous therapy , presence rheumatoid factor anti cyclic-citrullinated peptide antibody , Human Leukocyte Antigen ( HLA ) -B27 status , DAS28 score Health Assessment Questionnaire - HAQ ( Health Assessment Questionnaire , RA patient ) , BASDAI , Maastricht Ankylosing Spondylitis Enthesitis Score ( MASES ) , Bath Ankylosing Spondylitis Functional Index - BASFI ( AS patient ) Ankylosing Spondylitis Disease Activity Score ( ASDAS ) . Blood collect patient start treatment glucocorticoid disease-modifying anti-rheumatic drug ( DMARDs : methotrexate , sulphasalazine leflunomide ) 3 month reach stable dose drug . For latter start TNF-blockers blood sample collect 6 month start therapy . Because expect minority initial cohort need treat TNF antagonist , second group 25 RA 25 AS patient , select start TNF antagonist , assess start drug 6 month later . Written inform consent obtain patient prior protocol-specific procedure study conduct accordance regulation govern clinical trial Declaration Helsinki , amend Tokyo ( 2004 ) . This study approve HSM Ethics Committee . All procedures follow task perform RA AS patient ( serum blood ) healthy donor ( serum ) , unless state differently . Task 2 - Study inflammatory stimulus bone turnover marker Sub-populations immune system cell ( neutrophil , B T cell subpopulation , include Th17 cell ) analyse surface RANKL expression flow cytometry . Pro-inflammatory cytokine like IL-1β , IL-6 , IL-17A , IL-20 , IL-23 , TNF bone modulating protein ( OPG , sRANKL , sclerostin dickkopf-1 ) quantify ELISA . Bone degradation enzyme like tartrate-resistant acid phosphatase ( TRAP ) 5b bone turnover marker like type I collagen carboxyterminal cross-linked telopeptide ( ICTP ) procollagen type 1 amino-terminal propeptide ( P1NP ) also study . The data obtain flow cytometry experiment protein quantification compare disease treatment healthy donor . This allow u understand disease-specific difference systemic local inflammatory environment untreated patient effect different therapy environment . Task 3 - Analysis osteoclast precursor differentiation functional osteoclast Circulating CD14+ cell characterize analyse marker like HLA-DR , cluster differentiation ( CD ) 16 , CD86 , CD11b CD62L , well osteoclast differentiation-associated protein , surface integrin CD51/CD61 ( αVβ3 integrin ) , RANK ( receptor activator nf-kappa beta ) calcitonin receptor flow cytometry . In order fully characterize osteoclast precursor , expression osteoclast-related gene like DC-STAMP , MITF ( microphthalmia-associated transcription factor ) , CTSK ( cathepsin K ) , TRACP ATP6v0d2 CD14+ cell assess real time quantitative polymerase chain reaction ( RT-qPCR ) . The result obtain normalized housekeeping gene beta glucuronidase ( GUSB ) phosphomannomutase-1 ( PMM1 ) . Data obtain flow cytometry gene expression experiment compare treat untreated patient healthy donor . This task provide u quantitative information disease-specific change CD14+ monocytes subpopulation allow u understand effect therapy circulate precursor cell . Task 4 - Function cellular dynamic differentiate osteoclasts The isolated CD14+ monocyte culture 21 day presence M-CSF ( macrophage colony stimulate factor ) hrRANKL ( human recombinant receptor activator nf-kappa beta ligand ) 37º , 5 % CO2 multiwell culture plat . Osteoclasts analyze day 7 , 14 21 culture ass cellular dynamic . Expression osteoclast-specific gene analyze time-points RT-qPCR ( see Task 3 ) . Flow cytometry analysis perform assess CD51/CD61 RANK surface expression . Data obtain time point ( day 7 , 14 21 ) patient healthy control compare data obtain precursor cell . At 21st culture day cell use two functional assay : TRAP stain resorption assay . In TRAP stain assay assess number osteoclast form culture count TRAP-positive multinucleated cell 3 nucleus ( osteoclast ) . Comparison value nucleus count CD14+ monocytes culture plate allow u determine fusion index precursor . The resorption assay carry culture monocyte bone slice allow u measure resorption activity functional osteoclast . This measured image analysis bone slice stain toluidine-blue resorbed area acquire blue purple color . The analysis fusion rate precursor osteoclast resorbed area allow u identify difference osteoclast function RA AS patient healthy donor . Both monocyte osteoclast study regard RANK/RANKL αVβ3 integrin c-fms signalling pathway lead recruitment activation TRAF6 , tyrosine kinase Src extracellular signal-regulated kinase ( ERK ) 1/2 activate NF-kB transcription factor . These signal pathway study use Luminex xMAP platform EpiQuant Cell Signalling Assays ( Millipore ) . Comparison result untreated patient control allow u understand impairment osteoclast differentiation/activation classical pathway AS compare RA . The result obtain treated untreated patient provide insight action therapy osteoclast differentiation function . Comparing overall result untreated patient healthy donor allow u understand key difference osteoclast differentiation activation pathology . Task 5 - Function cellular dynamic osteoblast In subgroup RA AS patient submit either hip replacement cervical surgery osteoblast differentiation study . Immediately surgery , small piece trabecular bone ( 1cm3 ) extract sample order isolate osteoblast . After isolation , osteoblast culture Dulbecco 's minimal essential medium ( DMEM ) supplement vitaminD3 ( 10-8M ) cell study 80 % confluence . Osteoblasts ' function study vitro methylthiazole tetrazolium ( MTT ) assay ( cell proliferation ) , alkaline phosphatase stain mineralization nodule formation . Cells also use RNA extraction gene expression analysis Specific gene encode protein osteopontin , collagen type I , osteocalcin , alkaline phosphatase , RANKL , osteoprotegerin , runx2 osterix analyze characterize isolated cell . These result allow u understand difference osteoblast differentiation activity disease . Task 6 - Bone gene expression assay In subgroup RA AS patient submit either hip replacement cervical surgery frozen bone sample -80ºC . With bone still frozen , small sample trabecular bone reduce fine powder cryogenic mill RNA extraction perform use TRIzol reagent . The result RNA assess integrity quantify Bioanalyser . Therefore , RNA extract total RNA present bone , blood , osteoblast , osteoclast , osteocyte , adipocytes bone marrow cell . The gene expression bone microenvironment cell vitro study evaluate RT-PCR . Specific gene encode protein osteoblast osteoclast osteopontin , collagen type I , osteocalcin , alkaline phosphatase , RANKL , osteoprotegerin , runx2 , osterix , cathepsin K , beta3 integrin subunit , calcitonin receptor , ATPase subunit d2 , TRAF6 , RANK , TRAP , co-receptors OSCAR TREM-2 , among others , study . Osteocytes ' activity also assess expression specific gene , SOST , Dkk1 , DMP-1 , Phex , E11 antigen , MEPE CD44 . The gene code inflammatory cytokine IL-1 , IL-6 , IL-17 TNF also study . In order ass PCR efficiency , standard curve build RNA extract frozen bone sample individual normal bone mineral density disease could influence bone metabolism . The osteoclast , osteoblast osteocyte gene interest quantify standard curve method . The RNA expression study bone sample allow u understand local cell activity characterize bone cell function disease context .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Bone Resorption</mesh_term>
	<criteria>Patients RA diagnosis ( accord revise American Rheumatism Association criterion , 1988 ) AS diagnosis ( accord European Spondyloarthropathy Study Group criterion , 1991 ) follow Rheumatology Bone Metabolic Diseases Department Hospital de Santa Maria ( HSM ) recruit study . Patients active RA ( Disease Activity Score 28 ( DAS28 ) &gt; 3.2 ) active AS ( Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; 4 ) . Inactive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Osteoclasts</keyword>
	<keyword>TNF antagonist</keyword>
</DOC>